Latest action: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Referred to one or more standing committees for review, hearings, and possible markup.
Specific committees not parsed from action data.
The committee may hold hearings, amend the bill, or let it die without action.
Next: Reported
Full chamber floor — Speaker / Majority Leader controls scheduling
Requires homeopathic drug makers to prove safety, quality, and clearly label their products.
The problem
Homeopathic products lack consistent safety standards and transparent labeling, potentially misleading consumers about ingredients and effectiveness.
The proposal
Establishes FDA oversight for homeopathic drugs, requires safety testing, quality standards, and clear ingredient disclosure on product labels.
The impact
Homeopathic companies must meet new rules. Consumers get clearer information. Healthcare providers may see different product availability.
Clear labeling helps people know what they're buying. Customers can make informed choices about homeopathic products. Safety standards reduce potential harm from contaminated or mislabeled items.
Federal oversight creates consistent quality across the industry. Manufacturers meeting standards gain credibility. Consumers know products meet minimum safety requirements.
Transparency requirements prevent false or exaggerated health claims. Companies must prove what they advertise. Consumers aren't misled about product capabilities.
All manufacturers follow same rules, creating fair competition. Honest companies aren't undercut by those making false claims. Market becomes more stable and trustworthy.
New testing and compliance requirements cost money. Smaller homeopathic companies may struggle to afford safety testing. Costs could be passed to consumers through higher prices.
Some small manufacturers may exit the market if compliance costs are too high. Consumers lose access to certain products. Market consolidation toward larger companies may occur.
Bill may require effectiveness testing beyond what homeopathic practitioners consider appropriate. Disagreement exists over proper standards for homeopathic evaluation. Implementation details could be contentious.
New FDA oversight creates paperwork and administrative requirements for manufacturers. Small businesses spend resources on compliance instead of innovation. Government bureaucracy increases.
Generated by AI from the bill text. Not a prediction and not legal or policy advice. The percentage is the model's own rating of each item — self-reported, and not a measure of how accurate it is.
Loading map…
Loading...
0 citizens have already voted
Free · No spam · See how your representatives voted
Be the first to weigh in
Your vote starts the conversation
How citizen engagement works
Citizens vote & comment
Public opinion data is aggregated and updated in real time.
Patterns become visible
Representatives can see constituent sentiment broken down by district.
Your voice on the record
Contact your rep directly — one constituent call can shift a staffer's priority list.
Research shows that constituent contacts — especially calls — are among the most effective ways to influence a legislator's position on active bills.
Individual contributions, grouped by employer · FEC
Where their individual donors work · 2026 cycle
Money from people who work there, not from the company. Not tied to this bill.
Itemized individual contributions via FEC, grouped by the employer each contributor self-reported. Companies and unions cannot contribute to federal candidates from their treasuries, so these totals are money from people who work at an employer — never from the organization itself. They are campaign contributions covering a full election cycle and are not connected to this bill.
Senate LDA lobbying disclosures
Couldn't load lobbying disclosures right now.